TABLE 2

Noncompartmental analysis of serum 5-MeO-DMT PK in wild-type and Tg-CYP2D6 mice coadministered with harmaline and 5-MeO-DMT

Harmaline and 5-MeO-DMT were administered i.p. at 0 and 15 minutes, respectively.

Mice	Parameters	5-MeO-DMT 2 mg/kg				5-MeO-DMT 10 mg/kg
Mice	Parameters	Harmaline 0 mg/kg	Harmaline 2 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg	Harmaline 0 mg/kg	Harmaline 5 mg/kg	Harmaline 15 mg/kg
Wild-type	C_max (µM)	1.36 ± 0.16	1.88 ± 0.29^*	1.97 ± 0.15^*	1.93 ± 0.14^*	6.66 ± 1.13	13.3 ± 1.0^*	11.7 ± 1.5^*
Wild-type	AUC (µM⋅min)^{^a}	25.1 ± 1.3	97.6 ± 12.2^*	109.5 ± 14.3^*	134.0 ± 5.0^*	227 ± 41	759 ± 91^*	275 ± 27^*
Tg-CYP2D6	C_max (µM)	1.19 ± 0.33	1.90 ± 0.29^*	1.68 ± 0.39	2.26 ± 0.14^*^#	8.42 ± 1.03	10.4 ± 0.8^*^#	12.0 ± 1.8^*
Tg-CYP2D6	AUC (µM⋅min)^{^a}	21.1 ± 2.3^#	71.1 ± 13.3^*^#	76.3 ± 12.6^*^#	120.6 ± 5.1^*^#	249 ± 46	571 ± 11^*^#	264 ± 41^*

↵^a AUC_15→105min for the treatments of 5 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, AUC_15→45min for the treatments of15 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, and AUC_{15 min→∞} for all other treatments.
↵* P < 0.05 compared with corresponding values for the same genotype mice treated with the same dose of 5-MeO-DMT alone; ^#P < 0.05 compared with wild-type mice under the same treatment.